Here, we found that anti-PD1 alone or combined with anti-CTLA-4 delayed tumor growth significantly compared with anti-CTLA-4 alone (Figure 8), and adding OXi8007 to the combined regimen provided significantly enhanced overall survival, though no cures. The gene discussed is CTLA4; the disease is neoplasm.